Gensaic and Novo Nordisk Collaborate to Advance Next-Gen Precision Therapies
Total deal value of up to $354 million in upfront, development, and commercial milestone payments per target plus tiered royalties; Novo Nordisk also will reimburse R&D costs and participate...